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The endonuclease complex Ercc1/Xpf is involved in interstrand crosslink repair and functions downstream of the Fanconi pathway.
Loss of Ercc1 causes hematopoietic defects similar to those seen in Fanconi Anemia. Ercc1−/− mice die 3-4 weeks after birth, which
prevents long-term follow up of the hematopoietic compartment. We used alternative Ercc1 mouse models to examine the eﬀect
of low or absent Ercc1 activity on hematopoiesis. Tie2-Cre-driven deletion of a floxed Ercc1 allele was eﬃcient (>80%) in fetal
liver hematopoietic cells. Hematopoietic stem and progenitor cells (HSPCs) with a deleted allele were maintained in mice up to 1
year of age when harboring a wt allele, but were progressively outcompeted when the deleted allele was combined with a knockout
allele. Mice with a minimal Ercc1 activity expressed by 1 or 2 hypomorphic Ercc1 alleles have an extended life expectancy, which
allows analysis of HSPCs at 10 and 20 weeks of age. The HSPC compartment was aﬀected in all Ercc1-deficient models. Actively
proliferating multipotent progenitors were most aﬀected as were myeloid and erythroid clonogenic progenitors. In conclusion,
lack of Ercc1 results in a severe competitive disadvantage of HSPCs and is most deleterious in proliferating progenitor cells.
1. Introduction
The Ercc1/Xpf complex is an endonuclease involved in
nucleotide excision repair (NER) and in repair of interstrand
crosslinks (ICL) [1, 2]. Mice lacking Ercc1 (Ercc1−/−) suﬀer
from severe premature aging, which shows as small size,
ruﬄed fur, liver polyploidy, and loss of hematopoietic
progenitors from bone marrow (BM), resulting in death at
3-4 weeks of age [3–6]. Hypomorphic Ercc1 (Ercc1d/d or
Ercc1∗292) mice that harbor 2 C-terminally truncated alleles
are also small but they survive longer (∼6 months), probably
as a result of their residual DNA repair capacity (∼4%) [1, 2].
The hypomorphic allele has a 7 amino acid deletion at the C-
terminus, which impairs dimerization with Xpf [1].
The short life span and severe aging phenotype of
Ercc1−/− is shared with other models of defective NER such
as the Xpa−/− Csbm/m mice that die at 3 weeks of age [7–
9]. The hematopoietic defect of Ercc1−/− mice, however, is
specifically linked to defective ICL repair ([5]; Verhagen-
Oldenampsen et al., unpublished). The correlation of specific
phenotypes with either NER or ICL repair is likely due to
the activation of distinct tumor suppressor mechanisms that
impact diﬀerently on specific tissues. For instance, persistent
DNA damage due to defective NER results in deregulation of
the growth axis and is independent of p53 and p16INK4a [8].
Hematopoiesis, on the other hand, is particularly sensitive
to activation of p53 (Haanstra, Verhagen-Oldenampsen in
preparation).
Both fibroblasts and hematopoietic cells of Ercc1−/−
mice and mice lacking Fanconi proteins are hypersensitive
to the DNA crosslinker mitomycin C (MMC) [1, 5, 10].
Importantly, the endonuclease complex Ercc1/Xpf partici-
pates in the same ICL repair pathway as the Fanconi Anemia
(FA) proteins [11, 12]. It associates with FancP/Sxl4 and is
required for FancD2 focus formation [13, 14]. Mice lacking
for instance the Fancc gene only develop hematopoietic
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defects when challenged with MMC, or when hematopoietic
cells are cultured at atmospheric oxygen prior to transplan-
tation [10, 15]. Mice lacking Ercc1 develop hypoplasia of
the BM compartment without applying an external challenge
similar to FA patients [16] and Fancp/Slx4-deficient mice
[14].
The Ercc1 mice are a useful model to study BM failure
in FA, which is, however, limited by the short life span
of Ercc1−/− mice. The BM of Ercc1−/− mice contains fewer
progenitors, and the remaining myeloid and erythroid
progenitors fail to proliferate in vitro [5]. The aim of this
study was to characterize progression of BM failure in Ercc1
models with an extended life span, and to examine how low
levels of Ercc1 activity impact on hematopoiesis. We used
mice with a single floxed Ercc1 allele and a Tie2-driven Cre
recombinase. Tie2 is expressed in the early hematopoietic
stem cell (HSC) when they dissociate from the hemogenic
endothelium, and in quiescent adult HSC [17, 18]. We
show that the Ercc1 allele recombines eﬃciently in fetal
liver. In presence of an intact Ercc1 allele, the recombination
frequency remained stable, while the frequency of cells
lacking Ercc1 rapidly decreased in BM when the second
Ercc1 allele was lacking. This indicated that Ercc1-deficient
hematopoietic cells have a severe competitive disadvantage.
To investigate how low levels of Ercc1 aﬀect hematopoietic
stem and progenitor cells, we compared hematopoiesis in
mice harboring one or two hypomorph alleles (Ercc1−/d and
Ercc1d/d, encoding proteins with impaired Xpf dimerisation
capacity) at 3, 10, and 20 weeks of age. At week 3, we included
Ercc1−/− in this comparison. This analysis showed that
proliferating stem and progenitor cells decreased, whereas
the most immature cells within the LSK fraction were less
aﬀected once these cells became quiescent after 3 weeks of
age. The decrease of multipotent progenitors preceded the
decrease of committed progenitors indicating that the earliest
proliferating progenitors are most sensitive to defective ICL
repair.
2. Materials and Methods
2.1. Animals. Ercc1+/d, Ercc1+/− [1], Ercc1+/ f (obtained from
Dr. L. Niedernhofer, University of Pittsburgh School of
Medicine, Pittsburgh, PA), Tie2-Cre [19], and wt littermates
were kept in a pure background of both C57/Bl6 and FVB/n
at the Animal Resource Center (Erasmus MC). Experimental
animals were generated as F1 in a mixed background of
C57/Bl6 and FVB/n. Ercc1+/− and Ercc1+/d mice displayed
a wild-type phenotype and were used as controls. All
animal studies were approved by an independent Animal
Ethical Committee. Mice were sacrificed by CO2 inhalation
between postnatal weeks 3 and 20. Neonatal mice and
embryo’s were sacrificed by decapitation on ice. Femurs,
tibia, and sternum were isolated and BM cell suspensions
were obtained by crushing the bones in HBSS supplemented
with 5% (v/v) foetal calf serum, 100 units/mL penicillin, and
100 μg/mL streptomycin. Fetal livers and neonatal spleens
were resuspended by pipetting in the same medium.
2.2. Colony-Forming Unit Assays. Bone marrow cell suspen-
sions were plated in methyl cellulose medium (Methocult
M3234, StemCell Technologies SARL, Grenoble, France)
containing huGCSF (0.1 μg/mL), muGM-CSF (0.1 μg/mL),
or Epo (4mU/mL) plus transferrin (0.3mM), hemin
(0.2mM), and muSCF (0.1 μg/mL). Colonies containing 30
cells or more were scored after 7-8 days of culture.
2.3. Flow Cytometry. Single-bone-marrow cell suspensions
were analyzed by flow cytometry using a BD LSR II Flow
Cytometer System with FCS Express Diva software (BD
Biosciences, San Jose, CA). FCS files were analyzed using
FlowJo (Tree Star, Inc., Ashland, OR). Cells were labelled
with the following antibodies; mouse biotinylated lineage
depletion kit, CD16/CD32-PE, CD117-APC, CD135-PE
and streptavidin-APC-Cy7 (BD Pharmingen), Sca1-PE-Cy7,
CD34-pacific blue and CD127-pacific blue (Ebioscience),
and 7′AAD (Invitrogen).
2.4. Genotyping PCR and Q-PCR. Genomic DNA was iso-
lated from tail segments or from blood (NucleoSpin Tissue
XS, MACHEREY-NAGEL GmbH & Co). Genotypes were
determined by PCR. Genomic Q-PCR used an Applied
Biosystems 7900 instrument (Applied Biosystems, Weiter-
stadt, Germany) and SYBR Green PCR Master Mix (Applied
Biosystems). Primers used were HPRT—forward: AGC-
CTAAGATGAGCGCAAGT, reverse: ATGGCCACAGGA-
CTAGAACA; Recombined Ercc1 allele—forward: TGC-
AGCATGCTCTAGACTCG, reverse: CCATGAATTCCG-
GGATCTCTCGAC; nonrecombined Ercc1 allele—forward:
TCCACTTCGCATATTAAGGTGA, reverse: AACCTGCGT-
GCAATCCAT; Ercc1 knock out locus—forward: TCCTCG-
TGCTTTACGGTATC, reverse: CAGGATCAGGAGGTA-
CAGGA.
2.5. Histology. Livers were embedded in Tissue-Tek O.C.T
(Sakura Finetek, Zoeterwoude, Netherlands). 4 μm sections
were made using a cryostat (Leica) and stained with hema-
toxylin and eosin. Slides were imaged on a Leica DMLB
light microscope equipped with Leica application suite 2.7.1
(Leica Microsystems, Switzerland).
3. Results
3.1. Ercc1-Deficient Hematopoietic Stem and Progenitor Cells
Have a Competitive Disadvantage. Ercc1−/− mice have an
average lifespan of 3 weeks. Because we aimed to study
long-term eﬀects of Ercc1-deficiency on hematopoietic stem
cell function, we used a Cre-lox conditional mouse model
expressing Cre-recombinase from the Tie2 promoter (Tie2-
Cre). Tie2 is expressed on vascular endothelial cells andHSCs
[17, 18]. Mice with a single floxed Ercc1 allele (Ercc1+/ f )
were crossed with Ercc1+/− Tie2-Cre mice. We compared
Ercc1−/ f and Ercc1+/ f mice with and without expression of
Tie2-Cre. Because the recombination eﬃciency in Cre-lox
mouse models is never 100% [20], deletion of the floxed
allele was analyzed both pre- and postnatal in the most active
hematopoietic organ, that is, fetal liver in the embryo, spleen
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in newborn animals, and BM in adult animals. The presence
of the floxed allele was analyzed by real-time genomic PCR
on DNA isolated from the various tissues. The fraction of
cells with a deleted floxed allele was calculated by comparing
the relative signals in tissues with or without Cre. Tie2-
Cre/Ercc1+/ f mice showed stable deletion of the floxed allele
in 50% or more of the hematopoietic cells (Figure 1). In
Tie2-Cre/Ercc1−/ f mice, the Ercc1 allele was deleted in 80% of
fetal liver cells at prenatal days E12.5 and E15.5. In newborn
Tie2-Cre/Ercc1−/ f animals (postnatal day 1), ∼50% of spleen
cells carried a deleted floxed allele. At ten weeks of age,
the recombined allele was undetectable or present in a low
percentage of cells. In Tie2-Cre/Ercc1−/ f animals of 1 year
old, the BM contained hardly any cells with a recombined
allele (Figure 1). Accordingly, blood cell parameters and
colony-forming progenitors in BM were similar in Ercc1−/ f
mice with or without Tie2-Cre expression at 10 weeks and
1 year of age (data not shown). This indicates that Ercc1-
deleted cells are outcompeted by cells in which the floxed
allele was not recombined. The presence of one Ercc1 allele
is suﬃcient to maintain the hematopoietic cell compartment
at a similar level as in nondeleted animals.
3.2. The Composition of the Hematopoietic Stem Cell Pool Is
Aﬀected by the Level of Ercc1 Activity. To find a window of
Ercc1 expression that allows for the analysis of hematopoiesis
for several weeks, we compared hematopoiesis in bone mar-
row of Ercc1−/− mice with mice harboring one C-terminally
truncated Ercc1 allele and a knock out allele (Ercc1−/d),
or two C-terminally truncated Ercc1 alleles (Ercc1d/d). The
truncated allele has been described as ∗293 [1] or as delta
[21], we adopted delta, indicated as “d”, that should not to
be confused with a recombined floxed allele. Three-week-
old mice with low or absent Ercc1 activity had a dose-
dependent decrease in body size (Figure 2(a)). Ercc1−/− mice
died between weeks 3 and 4. The Ercc1d/d and Ercc1−/d mice
survived longer, but their low body weight persisted at 10 and
20 weeks of age (Figures 2(b) and 2(c)). A comparison of liver
morphology of the various Ercc1-deficient mice at 3 weeks
of age indicated that livers from both Ercc1−/−, Ercc1−/d, and
Ercc1d/d mice contained cells with enlarged nuclei, compared
to wt livers (larger than 8 μm; Figures 2(d) and 2(e)) as
previously described [21].
To analyze the eﬀect of low levels of Ercc1 on
hematopoiesis, we first examined the stem and progenitor
cell compartment using flow cytometry. Hematopoietic stem
cells and progenitor cells (HSPCs) were defined as negative
for lineage markers (Lin−) and positive for the surface
markers Sca (Sca1+) and the SCF receptor cKit (cKit+), indi-
cated as the LSK fraction. The stem cell compartment was
further subdivided into long-term HSC (LT-HSC, CD34−,
CD135−), short-termHSC (ST-HSC, CD34+ CD135−), and
multipotent progenitors (MPP, CD34+ CD135+) [22].
Because BM cellularity corrected for body weight was
comparable between the diﬀerent genotypes at 3, 10, and 20
weeks of age, a comparison of the subset ratios was permitted
between Ercc1-deficient mice and their wt littermates. The
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Figure 1: Recombination in Ercc1-flox Tie2-Cre model. The
fraction of recombined alleles in the presence of Tie2-Cre was
calculated after measuring the nondeleted floxed allele by real-time
genomic PCR and comparing it to the presence of the floxed allele in
absence of Cre. HPRT was measured to control for total DNA. DNA
was isolated from fetal livers at embryonic days E12.5 and E15.5,
from the spleen of neonatal mice, and from bonemarrow of 10- and
52-week-old mice. Closed triangles: Tie2-Cre; Ercc1+/ f , open boxes:
Tie2-Cre; Ercc1−/ f . Each symbol is an independent measurement.
percentage of LSK cells in the total bone marrow of 3-week-
old mice was decreased to 17% of wt for Ercc1−/−, 28% of wt
for Ercc1−/d, and 27% of wt in Ercc1d/d mice (Figure 3(a)).
At 10 weeks of age, the percentage of LSK cells present in
the BM further decreased in Ercc1−/d mice to 10% of wt but
stabilized to 50% of wt for Ercc1d/d mice (Figure 3(b)). At
20 weeks, the percentage of LSK was 26% of wt for Ercc1−/d
and 31% of wt for Ercc1d/d (Figure 3(c)). Thus, the size of
the stem cell compartment correlates with Ercc1 activity but
fluctuates over time.
We next investigated how distinct subpopulations within
the LSK compartment depend on Ercc1 protein activity.
The distribution of LT-HSC, ST-HSC, and MPP displayed
relatively minor changes at week 3 (Figure 3(d)). At 10
weeks of age, the fraction of actively dividing MPP was
more than 3-fold decreased in both hypomorphic models
(Figure 3(e)). The Ercc1−/d BM contained predominantly
quiescent LT-HSC, while proliferating ST-HSC was the
most abundant fraction in Ercc1d/d BM (Figure 3(e)). The
enrichment of quiescent LT-HSC is in accordance with the
further reduction of LSK in Ercc1−/d BM. In contrast, the
LSK fraction in Ercc1d/d BM partly recovered at week 10,
which is in accordance to the increase in ST-HSC fraction. At
20 weeks of age, the distribution of quiescent and dividing
subfractions within the population of LSK cells remained
similar to the distribution at 10 weeks for both Ercc1−/d and
Ercc1d/d mice (Figure 3(f)).
To specify the distribution of progenitors that arise
from the LSK fraction in relation to the remaining Ercc1
activity, we analyzed the following lineage committed
progenitor subsets: common myeloid progenitors (CMP,
Lin− cKit+ CD34+ CD16/CD32int), granulocyte-monocyte
progenitors (GMP, Lin− cKit+ CD34+ CD16/CD32hi),
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Figure 2: Weight and liver cell morphology of mice with distinct levels of Ercc1 activity. ((a)–(c)) Mean body weight of (a) 3-week-old
Ercc1−/− (n = 6), Ercc1−/d (n = 7), Ercc1d/d (n = 4), and wt (n = 13) mice. (b) 10-week-old Ercc1d/d (n = 3), Ercc1−/d (n = 3), and wt (n = 6)
mice. (c) 20-week-old Ercc1−/d (n = 8), Ercc1d/d (n = 5), and wt (n = 12) mice. (d) Hematoxylin- and eosin-stained sections of liver from
3-week-old wt, Ercc1−/−, Ercc1−/d , and Ercc1d/d mice. (e) Quantification of enlarged nuclei (>8 μm). Error bars indicate standard deviation.
∗indicates P ≤ 0.05, ∗∗indicates P ≤ 0.01, and ∗∗∗indicates P ≤ 0.001.
megakaryocyte-erythroid progenitors (MEP, Lin− cKit+
CD34− CD16/CD32low), and common lymphoid progen-
itors (CLP, Lin− CD127+ Sca1/cKit+ int). At 3 weeks
of age, the CMP fraction of Ercc1−/− mice decreased to
46% of wt, the GMP fraction to 16% of wt, the MEP
fraction to 45% of wt, and the CLP fraction to 48% of wt
levels (Figure 3(g)). In Ercc1−/d mice, the progenitor subsets
decreased to, respectively, 39%, 54%, and 88% of wt levels
and no change in CLP levels (Figure 3(g)). For Ercc1d/d
mice, these percentages were 23%, 38%, and 41% of wt
levels and no diﬀerence in CLP levels (Figure 3(g)). For all
myeloid subsets, except the CMP compartment, the numbers
increased in Ercc1−/d mice as compared to Ercc1−/− mice.
At 10 weeks of age, BM of Ercc1−/d mice contained 20%
of wt CMP levels, 29% of wt GMP levels, 49% of wt MEP
levels, and 87% of wt CLP levels (Figure 3(h)). In Ercc1d/d
mice, these subsets contained 32%, 27%, 39%, and 74%
of wt levels, respectively (Figure 3(h)). At 20 weeks of age,
Ercc1−/d BM contained 35% of wt CMP levels, 77% of wt
GMP levels, 53% of wt MEP levels, and 67% of wt CLP levels
(Figure 3(i)). In Ercc1d/d mice, these subsets contained 13%,
23%, 31%, and 69% of wt levels, respectively (Figure 3(i)).
In conclusion, decreased Ercc1 levels reduce all com-
partments of actively proliferating stem and progenitor cells
except for the CLP fraction that is only moderately aﬀected.
Despite reduced numbers of progenitors in BM, we observed
normal cell numbers in peripheral blood (data not shown).
The presence of a hypomorphic Ercc1 allele extends the life
span of the mice and marginally improves hematopoiesis
in the mice. Also in Ercc1d/d mice, the number of HSPCs
remains severely compromised.
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Figure 3: Ercc1 levels influence the composition of the stem and progenitor cell pool. Whole BM suspensions were stained with surface
antigen specific antibodies for hematopoietic stem cells. ((a)–(c)) LSK (Lin− Sca1+ cKit+) cells as percentage of total bone marrow cells.
((d)–(f)) Distribution of stem cells within the LSK fraction (LT HSC(CD34− CD135−), ST-HSC (CD34+ CD135−) and MPP (CD34+
CD135+)). ((g)–(i)) Distribution of progenitor cells within total bone marrow (CMP (Lin− cKit+ CD34+ CD16/CD32intermediate), GMP
(Lin− cKit+ CD34+ CD16/CD32high), MEP (Lin− cKit+ CD34− CD16/CD32low) and CLP (Lin− CD127+ Sca1/cKit intermediate)).
Mean percentages are plotted; error bars indicate standard deviation. ∗indicates P ≤ 0.05, ∗∗indicates P ≤ 0.01 and ∗∗∗indicates P ≤ 0.001.
3.3. Ercc1 Deficiency Impairs Colony Formation byHematopoi-
etic Progenitors. To assess the colony-forming potential of
hematopoietic progenitors, bone marrow suspensions were
plated in semisolid medium supplemented with lineage-
specific cytokines. At 3 weeks of age, the number of erythroid
(BFU-E, Figure 4(a)), granulocytic (CFU-G, Figure 4(b)),
and granulocytic-macrophage colony-forming cells (CFU-
GM, Figure 4(c)) were significantly reduced in all Ercc1-
deficient models relative to wt (Figures 4(a)–4(c)).
Similar results were obtained in BM of 10- and 20-week-
old mice; Ercc1−/d BM formed no BFU-E colonies (Figures
4(d) and 4(g)), no CFU-G colonies (Figures 4(e) and 4(h))
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Figure 4: Colony-forming potential of bone marrow progenitors is aﬀected in hypomorphic models or Ercc1. BFU-E, CFU-G, and CFU-
GM colonies per 5 × 104 bone marrow cells derived from ((a)–(c)) 3-week-old Ercc1−/− (n = 6), Ercc1−/d (n = 7), Ercc1d/d (n = 4), and wt
mice (n = 7) ((d)–(f)) 10-week-old Ercc1−/d (n = 3), Ercc1d/d (n = 3), and wt mice (n = 3), ((g)–(i)) 20-week-old Ercc1−/d (n = 3), Ercc1d/d
(n = 6), and wt mice (n = 8). Error bars indicate standard deviation. ∗indicates P ≤ 0.05, ∗∗indicates P ≤ 0.01, and ∗∗∗indicates P ≤ 0.001.
and only 31% of CFU-GM colonies compared to wt (Figures
4(f) and 4(i)). In Ercc1d/d BM, the percentages were 0%, 0%,
and 35% of wt, respectively. These results imply that the
residual Ercc1 activity in Ercc1−/d and Ercc1d/d mice is not
suﬃcient to support BFU-E or CFU-G colony formation,
whereas CFU-GM colony outgrowth is only partly restored.
4. Discussion
The Ercc1/Xpf endonuclease complex acts downstream of
the Fanconi pathway in ICL repair [1, 2, 12]. The hematopoi-
etic defects in Ercc1-deficient mice are reminiscent of the
hematopoietic defect of FA patients [23]. It mostly takes
several years before FA patients develop anemia. In most
FA mouse models, loss of HSC is only seen when the mice
are challenged with Mitomycin C [24, 25]. The fact that
most mouse models lacking Fanconi genes fail to display
overt BM failure may reflect the time it takes to develop
anemia. An important factor in the onset of BM failure and
leukemia development may be the level of residual DNA
repair activity. We employed Ercc1-deficient mouse models
to show progressive loss of the number of hematopoietic
stem and progenitor cells dependent on Ercc1 activity.
Remaining progenitors were compromised in their in vitro
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proliferation capacity, which was similarly severe in Ercc1−/−,
Ercc1−/d, and Ercc1d/d mice.
4.1. Reduced Competitiveness of Ercc1-Deficient Hematopoietic
Cells. The conditional knock out model showed that a small
percentage of hematopoietic stem and progenitor cells in
which the floxed Ercc1 allele did not recombine outcompeted
the Ercc1-deficient cells in which Cre-driven deletion had
occurred. This progressive loss of Ercc1-deficient hematopoi-
etic cells resembles what has been found in a small fraction
of FA patients. In some FA patients, a mutation was reverted
because two mutated alleles were recombined and yielded an
unaﬀected allele. Such a naturally corrected hematopoietic
stem cell is able to out-compete the hematopoietic cells
with two defective alleles resulting in the restoration of BM
cellularity. In these patients, the fibroblasts retained two
mutated alleles [26]. The conditional knock out mice that we
used here underscore that defective ICL repair mainly aﬀects
continuously regenerating tissues such as the hematopoietic
system. It is also in the continuously proliferating bone
marrow compartment that few cells with an intact allele can
out-compete cells that lack a functional FA pathway.
4.2. Reduced Hematopoietic Reserves with Normal Peripheral
Blood Levels. The hematopoietic defect in Ercc1-deficient
mice, and in FA, is specifically associated with DNA
crosslinks that stall the replication fork. The inability to
repair spontaneous DNA damage limits stress-hematopoiesis
by diminishing the ability of HSCs to proliferate and
self-renew. During embryo development and in young
mice (<3 weeks), the HSC compartment is continuously
expanded, whereas HSC become largely quiescent in adult
mice [27, 28]. These quiescent HSCs are less sensitive to
replication-coupled DNA damage repair defects. Progenitor
cells have a higher proliferation rate compared to HSC and
are, therefore, more prone to DNA damage both during
development and in adult mice. Accordingly, we found
that LSK numbers are 3- to 5-fold decreased compared to
their wt littermates in Ercc1-deficient mice. At 3 weeks of
age, the distribution within the LSK compartment hardly
shows a tendency towards more primitive cells, most likely
because all compartments contained proliferative cells. At
10 and 20 weeks of age, when the mice are adult, there is a
significant shift towards the more primitive cells in the LSK
compartment in the Ercc1−/d and Ercc1d/d compared to their
wt littermates, indicating that maintenance of the LT-HSC
fraction is less sensitive to DNA interstrand cross links than
the maintenance of the proliferative MPP fraction [29].
However, the mice did not develop overt anemia, and
peripheral blood contained near normal amounts of red and
white blood cells. This is most likely due to compensatory
mechanisms controlled by a network of cytokines and
hormones: only small and transient alterations in local-
and/or systemic concentrations will be needed to maintain
or restore homeostasis. Notably, Epo serum concentrations
were normal in Ercc1-deficient mice (data not shown), but
this result was expected given that the mice were not anemic
and Epo production in the kidney is activated by hypoxia.
Because cell numbers in peripheral blood are hardly
aﬀected, the hematopoietic defect in Ercc1−/d mice does
not represent overt BM failure but can be regarded as
a situation prone to such overt BM failure. Also in FA
patients, reduced stem cell numbers precede overt BM failure
and leukemia development [30, 31]. When challenged for
regeneration following insult, the Ercc1-deficient stem and
progenitor cells lack the robustness to do so. Analysis of
BM and leukemogenesis in FA and in FA mouse models
shows that hypoplasia precedes leukemic transformation
[32, 33]. Hypoplastic compartments are most at risk for
leukemic transformation [34]. FA patients mainly develop
acute myeloid leukemia (AML) and only very rarely acute
lymphoid leukemia (ALL) [35]. In the Ercc1 models, we also
found that the myeloid compartment is aﬀected by Ercc1
deficiency while the CLP compartment is hardly aﬀected.
Therefore, the hypomorphic Ercc1 mice may be a very useful
model to study BM failure mechanisms and subsequent
leukemogenic transformation in FA.
4.3. Comparison of the Hematopoietic Phenotype of Ercc1−/−,
Ercc1−/d, and Ercc1d/d Mice. In myeloid and erythroid
colony-forming assays, Ercc1-deficient progenitors show a
50% (on GM-CSF) to a 100% (on EPO/SCF or G-CSF)
decrease in colony numbers. In Ercc1−/d, and Ercc1d/d
mice, the decrease in colony numbers was not significantly
diﬀerent from those in Ercc1−/− mice. This implies that
low levels of functional protein cannot repair the damage
inflicted by the rapid proliferation that occurs in these assays.
Flow cytometry measurements indicated that the decrease
in myeloid and erythroid colony-forming cell numbers was
only moderate in the Ercc1-deficient models at 3 weeks of
age. Thus, the progenitors are present, and they are able to
generate progeny in vivo, but not in vitro. In vitro conditions
challenge the proliferation capacity more than the in vivo
condition andmay bemore mutagenic such as higher oxygen
levels.
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